Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma.
作者信息
Aydin Muruvvet Seda, Cengiz Esra, Can Ferda, Dagdas Simten, Dilek Imdat, Ozet Gulsum
机构信息
Department of Hematology and Bone Marrow Transplantation, Ankara Bilkent City Hospital, Ankara, Turkiye.
Department of Hematology, Sanliurfa Mehmet Akif Inan Education and Training Hospital, Sanliurfa, Turkiye.
出版信息
Blood Res. 2023 Dec 31;58(4):234-237. doi: 10.5045/br.2023.2023182. Epub 2023 Nov 15.
Abstract
摘要
相似文献
1
Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma.依鲁替尼联合吉西他滨-长春瑞滨治疗原发性难治性非霍奇金淋巴瘤。
Blood Res. 2023 Dec 31;58(4):234-237. doi: 10.5045/br.2023.2023182. Epub 2023 Nov 15.
2
Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.吉西他滨联合长春瑞滨方案在 ASCT 前用于复发或难治性霍奇金淋巴瘤的挽救和动员治疗是有效的。
Ann Hematol. 2011 Jun;90(6):685-91. doi: 10.1007/s00277-010-1113-z. Epub 2010 Nov 12.
3
Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.使用长春瑞滨、吉西他滨和非格司亭的晚期淋巴瘤门诊治疗方法的初步研究。
Intern Med J. 2007 Nov;37(11):760-6. doi: 10.1111/j.1445-5994.2007.01397.x. Epub 2007 Jun 2.
4
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.异环磷酰胺、吉西他滨和长春瑞滨是一种有效的挽救治疗方案，在复发或难治性小儿霍奇金淋巴瘤中具有极好的干细胞动员作用。
Pediatr Blood Cancer. 2020 Apr;67(4):e28167. doi: 10.1002/pbc.28167. Epub 2020 Jan 11.
5
Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin's lymphoma and primary mediastinal B cell lymphoma.低固定剂量派姆单抗联合吉西他滨、长春瑞滨、脂质体阿霉素（Pembro100 - GVD）作为复发难治性经典型霍奇金淋巴瘤和原发性纵隔B细胞淋巴瘤的有效挽救方案。
Ann Hematol. 2024 Jan;103(1):347-349. doi: 10.1007/s00277-023-05470-5. Epub 2023 Sep 23.
6
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.帕博利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星作为二线治疗复发或难治性经典型霍奇金淋巴瘤的 II 期临床试验。
J Clin Oncol. 2021 Oct 1;39(28):3109-3117. doi: 10.1200/JCO.21.01056. Epub 2021 Jun 25.
7
Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.吉西他滨和长春瑞滨化疗用于难治性或复发性侵袭性非霍奇金淋巴瘤
Hematol Oncol. 2012 Dec;30(4):214-5. doi: 10.1002/hon.2011. Epub 2012 Mar 16.
8
Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.吉西他滨、长春瑞滨、脂质体多柔比星（GVD）14 天方案作为挽救方案治疗既往大量治疗的霍奇金淋巴瘤和侵袭性非霍奇金淋巴瘤患者具有良好的长期疗效。
Med Oncol. 2013 Mar;30(1):350. doi: 10.1007/s12032-012-0350-5. Epub 2013 Jan 18.
9
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.一项多中心2期研究，评估含长春瑞滨和吉西他滨的风险调整挽救化疗方案用于复发难治性淋巴瘤的疗效。
Cancer. 2008 Dec 1;113(11):3192-8. doi: 10.1002/cncr.23915.
10
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.苯达莫司汀联合吉西他滨和长春瑞滨作为自体造血干细胞移植前诱导化疗治疗复发或难治性霍奇金淋巴瘤的有效方案：一项多中心 II 期研究的最终结果。
J Clin Oncol. 2016 Sep 20;34(27):3293-9. doi: 10.1200/JCO.2016.66.4466. Epub 2016 Jul 5.
本文引用的文献
1
Treatment of Richter's syndrome.里希特综合征的治疗。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):329-336. doi: 10.1182/hematology.2022000345.
2
Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment.弥漫性大B细胞淋巴瘤及其病理生物学新见解与治疗意义
J Family Med Prim Care. 2022 Aug;11(8):4151-4158. doi: 10.4103/jfmpc.jfmpc_2432_21. Epub 2022 Aug 30.
3
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".复发或难治性弥漫性大 B 细胞淋巴瘤：“困惑迷茫”。
Oncology (Williston Park). 2022 Jun 10;36(6):366-375. doi: 10.46883/2022.25920963.
4
Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.伊布替尼联合维奈托克治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
Ann Hematol. 2021 Jun;100(6):1509-1516. doi: 10.1007/s00277-021-04535-7. Epub 2021 Apr 26.
5
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma.ibrutinib 和来那度胺联合剂量调整 EPOCH-R 治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 1b/2 期研究。
Leuk Lymphoma. 2021 Sep;62(9):2094-2106. doi: 10.1080/10428194.2021.1907371. Epub 2021 Apr 15.
6
Revisiting Richter transformation in the era of novel CLL agents.重新审视新型 CLL 药物时代的 Richter 转化。
Blood Rev. 2021 Sep;49:100824. doi: 10.1016/j.blre.2021.100824. Epub 2021 Mar 12.
7
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.伊布替尼治疗弥漫性大 B 细胞淋巴瘤的疗效和安全性：一项单臂荟萃分析。
Crit Rev Oncol Hematol. 2020 Aug;152:103010. doi: 10.1016/j.critrevonc.2020.103010. Epub 2020 May 28.
8
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.针对复发或难治性弥漫性大 B 细胞淋巴瘤的新兴治疗方法。
Curr Oncol. 2019 Aug;26(4):253-265. doi: 10.3747/co.26.5421. Epub 2019 Aug 1.
9
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.一项关于伊布替尼联合 R-ICE 方案治疗复发或原发性难治性弥漫性大 B 细胞淋巴瘤患者的 1 期研究。
Blood. 2018 Apr 19;131(16):1805-1808. doi: 10.1182/blood-2017-08-802561. Epub 2018 Jan 31.
10
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.一项利妥昔单抗、苯达莫司汀和伊布替尼治疗未经治疗和复发/难治性非霍奇金淋巴瘤患者的 1 期/1b 期研究。
Blood. 2015 Jan 8;125(2):242-8. doi: 10.1182/blood-2014-08-597914. Epub 2014 Oct 29.
Zotero 插件